Daptomycin Activity against Staphylococcus aureus following Vancomycin Exposure in an In Vitro Pharmacodynamic Model with Simulated Endocardial Vegetations
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Recently, the emergence of reduced susceptibility to daptomycin has been linked to the reduced vancomycin susceptibility that occurs after vancomycin exposure in Staphylococcus aureus in vivo and in vitro. This study evaluated this propensity in clinical isolates of S. aureus using an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations over 8 days. Five clinical isolates (four methicillin-resistant S. aureus isolates and one methicillin-susceptible S. aureus [MSSA] isolate), all of which were reported to have become nonsusceptible to daptomycin, were evaluated. The following regimens were evaluated: vancomycin 1 g every 12 h for 4 days followed by daptomycin 6 mg/kg of body weight daily for 4 days and daptomycin 6 mg/kg daily for 8 days. If nonsusceptibility was detected, the following regimens were evaluated: no treatment for 4 days followed by daptomycin 6 mg/kg daily for 4 days, vancomycin 1 g every 12 h for 4 days followed by daptomycin 10 mg/kg daily for 4 days, and daptomycin 10 mg/kg daily for 8 days. The emergence of daptomycin nonsusceptibility (12- to 16-fold MIC increase) was detected only with the MSSA isolate with daptomycin 6 mg/kg daily for 4 days after vancomycin exposure. However, the bactericidal activity of daptomycin was maintained and the MIC increases of these isolates, which had no mprF or yycG mutations, were unstable to serial passage on antibiotic-free agar. Subsequent regimens did not demonstrate nonsusceptibility to daptomycin. These findings suggest that reduced daptomycin susceptibility can be a strain-specific and unstable event. Further evaluation of the susceptibility relationship between daptomycin and vancomycin is necessary to understand the factors involved and their clinical significance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DNA sequencing with chain-terminating inhibitors
Sanger, F., Nicklen, S., & Coulson, A. R. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.12.5463 · Cited by 68,572 · cited 1×
“Nucleotide sequence analyses were performed with the DS Gene program (version 1.5; Accelrys, Inc., San Diego, CA) ( 26 ).”
MethodInfluentialA modified microtiter-plate test for quantification of staphylococcal biofilm formation
Stepanović, S., Vuković, D., Dakić, I., Savić, B., & Švabić-Vlahović, M. (2000) · Journal of Microbiological Methods · doi:10.1016/s0167-7012(00)00122-6 · Cited by 2,550
Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus
Fowler, V. G., Boucher, H. W., Corey, G. R., Abrutyn, E., Karchmer, A. W., Rupp, M. E., Levine, D. P., Chambers, H. F., Tally, F. P., Vigliani, G. A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053783 · Cited by 1,459
Self-citationArbeit, R. D., Maki, D., Tally, F. P., Campanaro, E., Eisenstein, B. I., & Daptomycin 98-01 and 99-01 Investigators (2004) · Clinical Infectious Diseases · doi:10.1086/420818 · Cited by 689
Correlation of Daptomycin Bactericidal Activity and Membrane Depolarization in Staphylococcus aureus
Silverman, J. A., Perlmutter, N. G., & Shapiro, H. M. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.8.2538-2544.2003 · Cited by 656
Mwangi, M. M., Wu, S. W., Zhou, Y., Sieradzki, K., de Lencastre, H., Richardson, P., Bruce, D., Rubin, E., Myers, E., Siggia, E. D., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609839104 · Cited by 538
Cell Wall Thickening Is a Common Feature of Vancomycin Resistance in Staphylococcus aureus
Cui, L., Ma, X., Sato, K., Okuma, K., Tenover, F. C., Mamizuka, E. M., Gemmell, C. G., Kim, M.-N., Ploy, M.-C., El Solh, N., et al. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.1.5-14.2003 · Cited by 492
Howden, B. P., Ward, P. B., Charles, P. G. P., Korman, T. M., Fuller, A., Cros, P. D., Grabsch, E. A., Roberts, S. A., Robson, J., Read, K., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/381202 · Cited by 484
Genetic Changes That Correlate with Reduced Susceptibility to Daptomycin in Staphylococcus aureus
Friedman, L., Alder, J. D., & Silverman, J. A. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00039-06 · Cited by 454
Cui, L., Tominaga, E., Neoh, H.-M., & Hiramatsu, K. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.3.1079-1082.2006 · Cited by 427
Research works printed but not linked: 2
- Rose, W. E., M. J. Rybak, and G. Sakoulas. 2006. Daptomycin activity on S. aureus isolates pre and post exposure to vancomycin during the treatment for bacterial endocarditis, abstr. C1-0686. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
- Sheth, A., C. F. Carpenter, and B. Robinson-Dunn. 2006. Reduced vancomycin susceptibility and daptomycin nonsusceptibility associated with treatment failure in 2 cases of MRSA bacteremia, abstr. C2-1159. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
Cited by
Habib, G., Lancellotti, P., Antunes, M. J., Bongiorni, M. G., Casalta, J.-P., Del Zotti, F., Dulgheru, R., El Khoury, G., Erba, P. A., Iung, B., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv319 · Cited by 4,997
“For this reason, daptomycin should be given at high doses (≥10 mg/kg), and most experts recommend it be combined with beta-lactams(133) or fosfomycin(134) [beta-lactams (and probably fosfomycin) increase membrane daptomycin binding by decreasing the positive surface charge] for NVE and with gentamicin and rifampin for…”
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
Self-citationBaddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
“Histopathological evidence of bacteria with valve tissue Gram staining in patients with negative tissue cultures can represent killed organisms and is not a factor in defining the length of therapy after valve surgery.(110) For patients with NVE who undergo valve resection with prosthetic valve replacement or repair w…”
BackgroundSelf-citationGuidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009)
Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and by the International Society of Chemotherapy (ISC) for Infection and Cancer, Habib, G., Hoen, B., Tornos, P., Thuny, F., Prendergast, B., Vilacosta, I., Moreillon, P., de Jesus Antunes, M., Thilen, U., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp285 · Cited by 2,014
2023 ESC Guidelines for the management of endocarditis
Delgado, V., Ajmone Marsan, N., de Waha, S., Bonaros, N., Brida, M., Burri, H., Caselli, S., Doenst, T., Ederhy, S., Erba, P. A., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad193 · Cited by 1,754
Howden, B. P., Davies, J. K., Johnson, P. D. R., Stinear, T. P., & Grayson, M. L. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00042-09 · Cited by 962
“resistance (131, 283, 293, 348); however, these changes appear”
BackgroundClinical management of Staphylococcus aureus bacteraemia
Thwaites, G. E., Edgeworth, J. D., Gkrania-Klotsas, E., Kirby, A., Tilley, R., Török, M. E., Walker, S., Wertheim, H. F., Wilson, P., & Llewelyn, M. J. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70285-1 · Cited by 261
A Current Perspective on Daptomycin for the Clinical Microbiologist
Humphries, R. M., Pollett, S., & Sakoulas, G. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00030-13 · Cited by 240
Self-citationMechanisms of drug resistance: daptomycin resistance
Tran, T. T., Munita, J. M., & Arias, C. A. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12948 · Cited by 234
An RpoB Mutation Confers Dual Heteroresistance to Daptomycin and Vancomycin in Staphylococcus aureus
Cui, L., Isii, T., Fukuda, M., Ochiai, T., Neoh, H.-M., Camargo, I. L. B. D. C., Watanabe, Y., Shoji, M., Hishinuma, T., & Hiramatsu, K. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00437-10 · Cited by 206
“Various groups reported that MRSA with reduced susceptibility to vancomycin and/or daptomycin were generated during the treatment with either vancomycin or daptomycin (21, 26, 32, 42).”
BackgroundStaphylococcus aureus (Including Staphylococcal Toxic Shock)
QUE, Y.-A., & MOREILLON, P. (2010) · Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases · doi:10.1016/b978-0-443-06839-3.00195-8 · Cited by 172
The epidemiology of antibiotic resistance
Gould, I. M. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2008.06.016 · Cited by 174
“[7] Rose WE, Leonard SN, Sakoulas G, Kaatz GW, Zervos MJ, Sheth A, et al.”
BackgroundKullar, R., Davis, S. L., Levine, D. P., Zhao, J. J., Crank, C. W., Segreti, J., Sakoulas, G., Cosgrove, S. E., & Rybak, M. J. (2011) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.6.527 · Cited by 136
Self-citationMoise, P. A., North, D. S., Steenbergen, J. N., & Sakoulas, G. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70200-2 · Cited by 130
Self-citationTuning the properties of the bacterial membrane with aminoacylated phosphatidylglycerol
Roy, H. (2009) · IUBMB Life · doi:10.1002/iub.240 · Cited by 115
Rose, W. E., Schulz, L. T., Andes, D., Striker, R., Berti, A. D., Hutson, P. R., & Shukla, S. K. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00797-12 · Cited by 111
“High-dose therapies in these models particularly improve the efficacy of daptomycin against nonsusceptible strains compared to conventional doses of 6 mg/kg daily (20, 24).”
BackgroundSelf-citationTraunmüller, F., SCHINTLER, M. V., Metzler, J., Spendel, S., Mauric, O., Popovic, M., Konz, K. H., SCHARNAGL, E., & Joukhadar, C. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq109 · Cited by 106
Kullar, R., Casapao, A. M., Davis, S. L., Levine, D. P., Zhao, J. J., Crank, C. W., Segreti, J., Sakoulas, G., Cosgrove, S. E., & Rybak, M. J. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt294 · Cited by 99
Self-citationKosowska-Shick, K., Clark, C., Pankuch, G. A., McGhee, P., Dewasse, B. E., Beachel, L., & Appelbaum, P. C. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00742-09 · Cited by 106
“The unstable resistance mechanism detected in two clones in our study may be linked to reduced susceptibility to vancomycin, producing thickened cell wall due to excess production of peptidoglycan (9, 41, 46).”
BackgroundSakoulas, G., Rose, W., Nonejuie, P., Olson, J., Pogliano, J., Humphries, R., & Nizet, V. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02274-13 · Cited by 94
Self-citationManagement of methicillin-resistant Staphylococcus aureus infections
Garau, J., Bouza, E., Chastre, J. E., Gudiol, F., & Harbarth, S. (2009) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2009.02701.x · Cited by 100
“[44] evaluated the resistance of daptomycin after exposure to vancomycin in clinical S.”
BackgroundKatz, D. E., Lindfield, K. C., Steenbergen, J. N., Benziger, D. P., Blackerby, K. J., Knapp, A. G., & Martone, W. J. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01854.x · Cited by 93
Daptomycin: The role of high-dose and combination therapy for Gram-positive infections
Gould, I. M., Miró, J. M., & Rybak, M. J. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.05.005 · Cited by 93
Self-citationResch, G., François, P., Morisset, D., Stojanov, M., Bonetti, E.-J., Schrenzel, J., Sakwińska, O., & Moreillon, P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058187 · Cited by 81
“aureus (MRSA) [3], as well as last-resort vancomycin and daptomycin [4,5].”
BackgroundDuplessis, C. A., & Crum‐Cianflone, N. F. (2011) · Clinical Medicine Reviews in Therapeutics · doi:10.4137/cmrt.s1637 · Cited by 83
Berti, A. D., Wergin, J. E., Girdaukas, G. G., Hetzel, S., Sakoulas, G., & Rose, W. E. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00502-12 · Cited by 73
Self-citationOrtwine, J. K., Werth, B. J., Sakoulas, G., & Rybak, M. J. (2013) · Drug Resistance Updates · doi:10.1016/j.drup.2013.10.002 · Cited by 69
Self-citationSteed, M. E., Vidaillac, C., & Rybak, M. J. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00536-10 · Cited by 57
“aureus, as strains exhibiting elevated MICs often have only some or occasionally none of the above-mentioned changes (16, 17, 28).”
BackgroundSelf-citationKullar, R., Chin, J. N., Edwards, D. J., Parker, D. L., Coplin, W. M., & Rybak, M. J. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01741-10 · Cited by 58
“3505 symptoms alone or at least one of the aforementioned laboratory signs of CNS infection were classified as having suspected meningitis/ventriculitis.”
BackgroundInfluentialSelf-citationRoles of tRNA in cell wall biosynthesis
Dare, K., & Ibba, M. (2012) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1108 · Cited by 52
Kebriaei, R., Rice, S., Singh, K. V., Stamper, K. C., Dinh, A. Q., Ríos, R., Díaz, L., Murray, B. E., Munita, J. M., Tran, T. T., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00315-18 · Cited by 45
Self-citationCurrent and prospective treatments for multidrug-resistant gram-positive infections
Rybak, J. M., Barber, K. E., & Rybak, M. J. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.820276 · Cited by 45
“Described by Rose and colleagues, some isolates of staphylococci have demonstrated rapid development of reduced susceptibility to daptomycin following treatment with vancomycin [30].”
BackgroundSelf-citationStaphylococcus aureus (Including Staphylococcal Toxic Shock Syndrome)
Que, Y., & Moreillon, P. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00196-x · Cited by 54
Vancomycin-resistant enterococcal bacteraemia and daptomycin: are higher doses necessary?
King, E. A., McCoy, D., Desai, S., Nyirenda, T. L., & Bicking, K. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr255 · Cited by 41
Campanile, F., Borbone, S., Perez, M., Bongiorno, D., Cafiso, V., Bertuccio, T., Purrello, S., Nicolosi, D., Scuderi, C., & Stefani, S. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.06.044 · Cited by 39
Bicarbonate Resensitization of Methicillin-Resistant Staphylococcus aureus to β-Lactam Antibiotics
Ersoy, S. C., Abdelhady, W., Li, L., Chambers, H. F. “., Xiong, Y. Q., & Bayer, A. S. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00496-19 · Cited by 41
Timbrook, T. T., Caffrey, A. R., Luther, M. K., Lopes, V., & LaPlante, K. L. (2018) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2070 · Cited by 39
Steed, M. E., Werth, B. J., Ireland, C. E., & Rybak, M. J. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01185-12 · Cited by 37
Self-citationKullar, R., Davis, S. L., Kaye, K. S., Levine, D. P., Pogue, J. M., & Rybak, M. J. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1220 · Cited by 34
Self-citationJahanbakhsh, S., Singh, N. B., Yim, J., Kebriaei, R., Smith, J. R., Lev, K. L., Tran, T. T., Rose, W. E., Arias, C. A., & Rybak, M. J. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02074-19 · Cited by 35
Self-citationLeonard, S. N., & Rybak, M. J. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn439 · Cited by 35
“The question of daptomycin activity against strains of MRSA with reduced susceptibility to glycopeptides is a particularly relevant one as there have been several investigations that have found in vitro correlations between vancomycin and daptomycin susceptibility.(16,17,27,28) We found daptomycin to be highly active…”
BackgroundSelf-citationCrompton, J. A., North, D. S., Yoon, M., Steenbergen, J. N., Lamp, K. C., & Forrest, G. N. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq200 · Cited by 30
High-Dose Daptomycin Therapy for Staphylococcal Endocarditis and When to Apply It
Smith, J. R., Claeys, K. C., Barber, K. E., & Rybak, M. J. (2014) · Current Infectious Disease Reports · doi:10.1007/s11908-014-0429-6 · Cited by 31
“Rose and colleagues evaluated clinical isolates exposed to vancomycin followed by either daptomycin 6 or 10 mg/kg every 24 h in an in vitro pharmacokinetic/pharmacodynamic (PK/PD) model with simulated endocardial vegetations (SEVs) over an 8-day period [31].”
Self-citationLa endocarditis infecciosa en el siglo xxi: cambios epidemiológicos, terapéuticos y pronósticos
Fernández‐Hidalgo, N., & Almirante, B. (2012) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2011.11.005 · Cited by 50
“%) y el tama ˜ no de las Tabla 6”
BackgroundHabib, G., Hoen, B., Tornos, P., Thuny, F., Prendergast, B., Vilacosta, I., Moreillon, P., Antunes, M. J., Thilén, U. J., Lekakis, J. P., et al. (2009) · Revista Española de Cardiología · doi:10.1016/s0300-8932(09)73131-8 · Cited by 43
Rose, W. E., Bienvenida, A. M., Xiong, Y. Q., Chambers, H. F. “., Bayer, A. S., & Ersoy, S. C. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02072-19 · Cited by 27
“274 275 The ex vivo simulated endocardial vegetation (SEV) model has been extensively used to 276 pharmacokinetically and pharmacodynamically study the impacts of many antimicrobials against 277 several clinical bacterial isolates in order to verify these interactions in a setting more akin to the 278 host tissue micr…”
MethodSelf-citationSteed, M. E., Vidaillac, C., & Rybak, M. J. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05849-11 · Cited by 23
Self-citationPre-clinical in vitro infection models
Drusano, G. L. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.09.011 · Cited by 23
George, J., Newman, J. M., Klika, A. K., Miller, E. M., Tan, T. L., Parvizi, J., & Higuera, C. A. (2018) · The Journal of Arthroplasty · doi:10.1016/j.arth.2018.01.056 · Cited by 24
Mishra, N. N., Lew, C., Abdelhady, W., Lapitan, C. K., Proctor, R. A., Rose, W. E., & Bayer, A. S. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01649-21 · Cited by 26
“The efficacy of DAP1/2Fosfo in synergy, preventing evolution of DAP-R and/or resensitizing the DAP-R strain to a DAP-S phenotype, was assessed over a 96-h ex vivo exposure period, allowing adequate time for DAP-R to emerge (30, 31).”
MethodSelf-citationTwele, L., Moyen, E., Zhang, K., Dalton, B., Church, D. L., & Conly, J. M. (2010) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2010/618953 · Cited by 22
“Rose et al (24) evaluated five clinical isolates of S aureus (four MRSA isolates and one methicillin-susceptible S aureus isolate) with reduced susceptibility to daptomycin following vancomycin therapeutic exposure in an in vitro pharmacodynamic model.”
BackgroundInfluentialBowker, K. E., Noel, A. R., & MacGowan, A. P. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp289 · Cited by 20
Bhalodi, A. A., Hagihara, M., Nicolau, D. P., & Kuti, J. L. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01516-13 · Cited by 19
“In a similar study done by Rose and colleagues to determine the effects of daptomycin activity after vancomycin exposure, no changes in the MICs were detected for any MRSA isolates that were treated with daptomycin following vancomycin exposure for 4 days (33).”
BackgroundChang, J. H. T., Tasellari, A., Wagner, J. L., & Scheetz, M. H. (2023) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2275663 · Cited by 22
“Although high-dose daptomycin appears to be safe and well tolerated among healthy volunteers [157,158], it should be mentioned that the 10 mg/kg/day dose is primarily based on limited in vitro evidence that suggest higher daptomycin doses may slow emergence of MRSA resistance [159,160].”
BackgroundOptimizing therapy for vancomycin-resistant enterococcal bacteremia in children
Tamma, P. D., & Hsu, A. J. (2014) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000115 · Cited by 18
Ersoy, S. C., Rose, W. E., Patel, R., Proctor, R. A., Chambers, H. F. “., Harrison, E. M., Pak, Y., & Bayer, A. S. (2021) · Antibiotics · doi:10.3390/antibiotics10091089 · Cited by 13
“4 g/dL of total protein (equating to human physiologic levels) [53,54].”
BackgroundSelf-citationInnovative Management of Recurrent Furunculosis
Atanaskova, N., & Tomecki, K. J. (2010) · Dermatologic Clinics · doi:10.1016/j.det.2010.03.013 · Cited by 12
“Its half-life is 8 hours, and most of the drug is excreted by the kidney, nonmetabolized.(44) Daptomycin is the drug of choice for patients with severe MRSA infections or bacteremia who are intolerant of vancomycin or for patients with VRSA infections, which are daptomycin susceptible.”
BackgroundSteed, M. E., Hall, A. D., Salimnia, H., Kaatz, G. W., Kaye, K. S., & Rybak, M. J. (2013) · Infectious Diseases and Therapy · doi:10.1007/s40121-013-0021-7 · Cited by 12
“aureus strain recovered previously from an in vitro PK/PD model reverted back to its susceptible state after serial passage on drug free agar [35].”
BackgroundSelf-citationVidaillac, C., Steed, M. E., & Rybak, M. J. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01291-10 · Cited by 11
“ATCC 9341, as previously described (35).”
Self-citationLê, J., Dam, Q., Schweizer, M. L., Thienphrapa, W., Nizet, V., & Sakoulas, G. (2016) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-016-2682-0 · Cited by 10
“In one case in particular, daptomycin achieves remarkable (sometimes 4 log10 CFU reduction in 4 h) killing in vitro under standard CLSI killing assays, but does not offer any difference in shortening the duration of MSSA or MRSA bacteremia over standard therapy [21].”
BackgroundSelf-citationBasco, M. D. S., Kothari, A., McKinzie, P. B., Revollo, J. R., Agnihothram, S., Azevedo, M. S. P., Saccente, M., & Hart, M. E. (2019) · Journal of Medical Microbiology · doi:10.1099/jmm.0.000988 · Cited by 10
Townsend, J. A., & Marty, M. T. (2023) · Methods · doi:10.1016/j.ymeth.2023.07.004 · Cited by 9
Ross, J. K., Rankin, S., Marshik, P. L., Mercier, R.-C., Brett, M., & Walraven, C. J. (2015) · Antibiotics · doi:10.3390/antibiotics4030309 · Cited by 8
“aureus strains have described a phenomenon in which prior exposure to vancomycin resulted in reduced daptomycin susceptibilities [7,8].”
BackgroundNew therapeutic approach for the treatment for staphylococcal bacteremia and sepsis
Борисович, Б. В. (2014) · Epidemiology and Infectious Diseases · doi:10.17816/eid40824 · Cited by 6
Papachatzi, E., Gkentzi, D., Tzifas, S., Dassios, T. G., & Dimitriou, G. (2024) · Antibiotics · doi:10.3390/antibiotics13030254 · Cited by 5
Management of MRSA/GISA, VISA Endocarditis
Jacqueline, C., Caillon, J., & Boutoille, D. (2013) · Current Infectious Disease Reports · doi:10.1007/s11908-013-0349-x · Cited by 4
“, 8–12 mg/kg/d) should prevent the emergence of resistance [56, 57].”
BackgroundHoen, B., Tornos, P., Antunes, M. J., Lekakis, J. P., Lengyel, M., Naber, C. K., & Zamorano, J. L. (2009) · Cited by 3
Therapeutic Drug Monitoring: More Than Avoiding Toxicity
Stojanova, J., & Luque, S. (2017) · Springer eBooks · doi:10.1007/978-981-10-5336-8_9 · Cited by 3
Habib, G., Hoen, B., Tornos, P., Thuny, F., Prendergast, B., Vilacosta, I., Moreillon, P., Antunes, M. J., Thilén, U. J., Lekakis, J. P., et al. (2009) · Revista Española de Cardiología (English Edition) · doi:10.1016/s1885-5857(09)73540-6 · Cited by 3
Daptomycin: Pharmacokinetic, Pharmacodynamic, and Dose Optimization
Vidaillac, C., & Rybak, M. J. (2013) · Springer eBooks · doi:10.1007/978-0-387-75613-4_15 · Cited by 1
Self-citationНовые возможности лечения бактериемии и сепсиса вызванных стафилококками
Борисович, Б. В. (2014) · Epidemiology and Infectious Diseases
Beleslin, B., Deljanin, M., Kanjuh, V., Parapid, B. J., Giga, V. L., Prostran, M. S., Angelkov, L., Balinovac, J., Bikicki, M., Ambrosio, G., et al. (2013)
Vilacosta, I., Blanco, C. O., Cepeda, C. S., Díaz, J. L., Durán, C. F., & Calvar, J. A. S. R. (2016) · Springer eBooks · doi:10.1007/978-3-319-32432-6_15
“Nowadays, when using daptomycin, most authors recommend using high doses (10 mg/kg/24 h) and combining it with cloxacillin or fosfomycin to avoid the development of drug resistance [ 51 ].”
BackgroundTennant, S. (2016) · UKnowledge (University of Kentucky) · doi:10.13023/etd.2016.298
“to vancomycin for 4 days followed by daptomycin simulated at 6 mg/kg or 10 mg/kg for 4 days.(91) Daptomycin retained activity against all strains with no difference in time to achieve 99.”
MethodCurrent challenges in treating methicillin-resistant Staphylococcus aureus : what are the options?
Sakka, N. E., & Gould, I. M. (2013) · Microbial Drug Resistance · doi:10.2217/ebo.12.485
Daptomycin in the treatment of infective endocarditis
Попов, Д. А. (2018) · Clinical Microbiology and Antimicrobial Chemotherapy · doi:10.36488/cmac.2018.1.35-40
(2009) · Current Opinion in Otolaryngology & Head & Neck Surgery · doi:10.1097/moo.0b013e32832406ce
Smith, J. R., Claeys, K. C., Zasowski, E. J., Yim, J., & Rybak, M. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-46718-4_21
Self-citationCombined Antimicrobial Therapy for Infective Endocarditis
Gomez-Villegas, S. I., Miller, W. R., & Arias, C. A. (2024) · Springer eBooks · doi:10.1007/978-3-031-65839-6_16
Jaiswal, R., Verma, A., Venkatesh, V., Garg, A., & Tripathi, A. (2025) · Journal of Laboratory Physicians · doi:10.25259/jlp_39_2025
Metadata
- Authors
- Rose, W. E., Leonard, S. N., Sakoulas, G., Kaatz, G. W., Zervos, M. J., Sheth, A., Carpenter, C. F., & Rybak, M. J.
- Affiliations
- Eugene Applebaum College of Pharmacy and Health Sciences (US)
- New York Medical College (US)
- Wayne State University (US)
- Beaumont Health (US)
- Corresponding author
- Rybak, Michael J.
- ORCID
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2008-03
- Volume
- 52
- Issue
- 3
- Pages
- 831-836
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC2258488
- OpenAlex
- W2147152367
- Semantic Scholar
- 1d34226df52261b6c8a02321749f5b66076f3f8f
- Cited by
- 81
- References
- 28
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 3 · 2021: 2 · 2020: 1 · 2019: 3 · 2018: 3 · 2017: 4 · 2016: 3 · 2015: 5 · 2014: 4 · 2013: 14 · 2012: 6
- FWCI
- 4.61
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Keywords
- daptomycin, Staphylococcus aureus, endocarditis, endocardial vegetation, pharmacokinetic-pharmacodynamic modeling, methicillin-resistant Staphylococcus aureus, methicillin-susceptible Staphylococcus aureus, mprF, antibiotic resistance emergence, bactericidal activity
- MeSH terms
- Anti-Bacterial Agents, Culture Media, Drug Therapy, Combination, Endocarditis, Bacterial, Humans, Methicillin, Microbial Sensitivity Tests, Models, Biological, Staphylococcus aureus, Vancomycin, Methicillin Resistance, Daptomycin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.